Table 2 Logistic regression analysis for UTRN expression and clinical characteristics in TCGA patients
From: UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways
Characteristic | N | OR | P value |
|---|---|---|---|
T (T1T2 vs. T3T4) | 399 | 0.57 (0.36–0.87) | 0.01 |
N (N0 vs. N1N2) | 344 | 1.05 (0.68–1.64) | 0.82 |
M (M0 vs. M1) | 423 | 1.11 (0.46–2.72) | 0.81 |
Clark level (I/II/III vs. IV/V) | 309 | 0.54 (0.33–0.88) | 0.01 |
Ulceration (no vs. yes) | 304 | 0.59 (0.37–0.92) | 0.02 |
Site (extremities vs. trunk) | 355 | 1.11 (0.73–1.68) | 0.64 |
Age (< 60 vs. ≥ 60) | 447 | 0.78 (0.54–1.14) | 0.20 |
Gender (female vs. male) | 447 | 1.2 (0.82–1.76) | 0.35 |
Height (< 170 vs. ≥ 170) | 234 | 1.52 (0.90–2.55) | 0.12 |
Cancer status (tumor free vs. with tumor) | 423 | 1.34 (0.92–1.97) | 0.13 |
Race (Asian vs. White) | 438 | 1.77 (0.53–6.86) | 0.37 |
Radiation therapy (no vs. yes) | 405 | 1.19 (0.72–1.98) | 0.50 |
Weight (< 80 vs. ≥ 80) | 240 | 178 (1.07–2.98) | 0.03 |